Indom

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Indom

Property Description
Active ingredient Indometacin (Indomethacin)
Pharmacological class Nonsteroidal Anti-Inflammatory Drug (NSAID)
Form Capsules, suppositories, gel, ophthalmic solution
Common use Relief of pain, inflammation, and fever
Origin Synthetic compound (indole derivative)

What is Indom and Its Core Composition?

Indom is a medicinal preparation whose active substance is Indometacin (or Indomethacin). As an indole derivative, this potent compound is entirely synthetic, confirming its origin as a manufactured entity rather than a naturally derived substance. Indometacin is primarily a single-active ingredient drug that is classified for prescription use (Rx), reflecting its potency. It is available in various dosage forms, including oral capsules, suppositories for rectal use, and topical preparations like gels, allowing for both systemic and localized administration.


What Type of Medicine is Indom?

Indom is definitively classified as a Nonsteroidal Anti-Inflammatory Drug (NSAID). This grouping establishes the drug as a non-opioid agent intended to act directly on inflammatory and pain signaling pathways. Indometacin is recognized for being a potent NSAID; its primary action involves non-selective inhibition of the cyclooxygenase (COX) enzyme system, which is essential for creating the chemical triggers of pain and inflammation. Indometacin is a widely studied NSAID utilized for its inhibitory action on prostaglandin synthesis. Clinical studies support that this medicine is effective at easing discomfort and swelling.


What are the General Benefits of Indom?

The overall utility of Indom is defined by its capacity to provide a triple-action benefit: it is a strong agent for the relief of pain, the reduction of inflammation, and the lowering of fever. It achieves this by working at a molecular level to effectively block the body’s production of prostaglandins. Indometacin is utilized for its efficacy in controlling symptoms where inflammation and pain are primary concerns. Pharmacological research demonstrates the drug’s high potency compared to many other agents in the same class. This combination of analgesic, anti-inflammatory, and antipyretic effects establishes Indom as a valuable agent against the symptomatic manifestations of both localized and systemic inflammatory states.

What side effects are possible with Indom?

Possible side effects and safety information

The official safety information for Indometacin is structured by regulatory bodies to communicate potential adverse reactions and safety characteristics. The medicine carries label-documented risks for serious cardiovascular thrombotic events (such as myocardial infarction and stroke) and severe gastrointestinal events (including bleeding, ulceration, and perforation), which can be fatal. These risks are noted to generally increase with the duration of use.

Adverse reactions are classified by frequency across various organ systems:

Classification System-Organ Class Examples
Common Headache, dizziness, dyspepsia, nausea, abdominal pain (Gastrointestinal, Nervous System)
Rare Gastrointestinal ulceration, acute kidney injury, severe cutaneous reactions (Gastrointestinal, Renal, Skin)

Use is contraindicated for the management of peri-operative pain in the setting of coronary artery bypass graft (CABG) surgery and in patients with severe organ failure (e.g., severe heart, hepatic, or renal failure). Population-specific safety notes highlight that older adults have an increased frequency and severity of adverse reactions, particularly serious gastrointestinal and renal events. Additionally, use after approximately 30 weeks of pregnancy is restricted due to the documented risk of premature closure of the fetal ductus arteriosus.

Regulatory documentation also notes that the medicine may lead to new-onset or worsening hypertension and may mask the signs and symptoms of underlying infection.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose with Indometacin (Indom) is a serious event requiring regulatory-mandated emergency action. The official prescribing information documents a range of clinical signs, with potential for severe, life-threatening outcomes.


Documented Overdose Manifestations

System Officially Documented Symptoms and Outcomes
Gastrointestinal Nausea, vomiting, severe stomach pain; potential for gastrointestinal bleeding.
Central Nervous System Severe headache, dizziness, confusion, disorientation, lethargy, tremors, and the severe outcome of seizures.
Systemic/Renal Hypotension (low blood pressure), metabolic acidosis, and the life-threatening complication of acute renal failure (kidney damage).

Emergency Actions and Management Status

Seek immediate medical attention or contact emergency services immediately upon the suspicion of an overdose or if any severe manifestations, such as seizures or significant bleeding, are observed. Hospital monitoring is required.

The regulatory profile confirms that no specific antidote is known for Indometacin overdose. Therefore, the official management is strictly limited to symptomatic and supportive treatment. This may include procedures such as gastric lavage or the administration of activated charcoal, alongside close clinical monitoring of vital signs and kidney function.

Therapeutic Uses of Indom

What Indom Treats: Main Uses and Benefits

The utility of Indometacin provides supportive symptom management across key domains of inflammation, pain, and fever. It is relevant in clinical settings marked by heightened distress and fluctuating symptom patterns. The medicine is utilized in situations involving recurrent or episodic manifestations.

This medication is commonly used to help manage symptoms associated with conditions such as rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, and acute events like gouty arthritis and localized inflammation (e.g., bursitis). It is applied in situations involving certain distressing symptoms, where it may assist with easing the overall symptom burden of persistent pain, swelling, and stiffness.

Its therapeutic application is relevant for easing distress and supports patients during difficult episodes.

It is commonly used across conditions presenting with acute episodes, where symptomatic relief is needed to support comfort and daily functioning.

Indometacin is also considered relevant in specialized contexts, including managing postoperative ocular inflammation and specific Indometacin-responsive headache disorders. This approach may contribute to improved comfort during symptomatic periods and can assist with maintaining functional stability when symptoms interfere with routine activities.

Quick Fact: Focuses on three symptom areas
Symptom Support: Provides supportive management for three distinct symptom axes: inflammatory symptoms (swelling), acute and chronic pain (discomfort), and systemic manifestations (fever).

Eligibility and Restrictions for Use

Who Can and Cannot Use Indom?

Eligibility for Indom (Indometacin) is strictly determined by regulatory guidelines, focusing on populations that are contraindicated or require special caution. This information is based solely on official labeling from government health authorities.


Absolute Non-Eligibility (Contraindications)

Indom is strictly contraindicated and must not be used by individuals with the following conditions:

  • A known allergy or hypersensitivity to indomethacin or any other NSAID (Nonsteroidal Anti-Inflammatory Drug), including a history of aspirin-sensitive asthma.
  • Treatment of peri-operative pain in the setting of Coronary Artery Bypass Graft (CABG) surgery.
  • Presence of an active gastrointestinal (GI) ulcer or bleeding.
  • During the third trimester of pregnancy (starting at 30 weeks gestation).

Populations Requiring Conditional Use

Population/Condition Regulatory Requirement (Limited Use)
Pediatric Use Safety and efficacy not established for children under 14 or 15 years of age for most forms.
Older Adults (Geriatric) Requires greater care and closer monitoring due to increased risk of GI and renal events.
Renal/Heart Failure Use must be avoided in patients with severe impairment unless the benefits outweigh the risk of worsening function.
Breastfeeding Not recommended due to excretion in breast milk and potential for adverse reactions in the infant.

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

Indomethacin's interaction profile is documented by regulatory authorities, highlighting combinations that may affect drug exposure or increase the risk of adverse events. Co-administration should be carefully considered based on official labeling.

Documented Interaction Categories

Interaction Type Examples of Interacting Substances/Classes
Increased Systemic Exposure Lithium, Digoxin, Methotrexate, Probenecid
Diminished Efficacy ACE Inhibitors, ARBs, Beta-Blockers, Diuretics
Additive Adverse Risk Other NSAIDs (e.g., Ketorolac), Warfarin, SSRIs, Alcohol

Key Interaction Restrictions

Co-administration with Ketorolac is not recommended due to enhanced toxicity risk. Use is also restricted for the treatment of peri-operative pain associated with Coronary Artery Bypass Graft (CABG) surgery. The concurrent use of Indomethacin with anticoagulants (like Warfarin) or anti-platelet agents (including certain antidepressants) significantly raises the documented risk of gastrointestinal bleeding, necessitating close monitoring. The increase in plasma concentrations of narrow therapeutic index drugs like Lithium and Digoxin requires mandatory serum level monitoring to prevent toxicity. In the elderly or those with renal impairment, interactions with anti-hypertensive agents that can worsen renal function are noted as a particular concern.

Mechanism of Action

The drug acts primarily by functioning as a non-selective competitive inhibitor of the Cyclooxygenase (COX) enzyme system, targeting both COX-1 and COX-2 isoforms. This molecular blockade interrupts the Arachidonic Acid Cascade, halting the synthesis of prostanoids—the key lipid mediators that regulate inflammatory and nociceptive signaling pathways. The mechanism operates by interfering with signaling cascades in which these mediators dominate. The molecular action results in two core physiological consequences. By decreasing the local concentration of prostaglandins, the drug limits the sensitization of peripheral nociceptors (sensory neurons), resulting in modulation of nociceptive signaling. Simultaneously, the drug exerts a central effect by inhibiting PGE2 production within the hypothalamus, effectively resetting the brain's elevated thermal set-point associated with pyrogen-induced states. These integrated mechanisms result in predictable physiological adjustments, modulating activity within the body's nociceptive and thermoregulatory systems. The non-selective nature is associated with a functional constraint, as inhibition extends to COX-1, which produces prostaglandins involved in essential homeostatic regulation.

Dosage and Administration Information

Indom is administered via several officially designated routes, including oral (capsules and suspension), rectal (suppositories), and specialized intravenous (IV) injection. The general administration protocol mandates using the lowest effective dosage for the shortest duration consistent with treatment goals.

For chronic conditions, the oral regimen typically starts with 25 mg two or three times daily. The total daily dose is subject to titration, where the amount may be gradually increased by 25 mg or 50 mg increments at weekly intervals; however, the total dose for immediate-release forms must not exceed 200 mg. Administration guidelines suggest that oral forms are generally taken with food to align with proper use. A portion of the dose, up to 100 mg, may be taken at bedtime to manage nocturnal symptoms.

Specific formulations carry distinct handling requirements. The extended-release capsules (75 mg) are designated for once daily use and must not be crushed, broken, or chewed to preserve the medication's release profile. In acute conditions like gouty arthritis, a higher initial dose (50 mg three times daily) is prescribed, with the instruction that the dose should be rapidly reduced to cessation upon relief. The IV route, which involves a weight-based (mg/kg) regimen, is reserved for specialized neonatal applications and requires prior reconstitution with a preservative-free diluent.

Recent Clinical Evidence

Research Evidence / Overview of Studies


Summary of Key Research Findings

Research into Indom (the compound) and its specific combination has focused on the compound's investigation in areas related to pain and inflammatory conditions. Early studies, primarily observational, were followed by randomized controlled trials (RCTs) that examined various dosing protocols. The primary objective of this research was to determine potential associations between the compound's exposure and measurements of patient-reported outcomes.


Evidence in Chronic Pain Conditions

Clinical research was investigated for its application in studies concerning chronic pain. In a Phase II RCT, 200 participants with diagnosed osteoarthritis were divided into two groups: one receiving the compound combination and one receiving a placebo.

  • Pain Reduction: Researchers evaluated whether the combination was associated with a change in pain scores over a 12-week period. The primary endpoint measured the average change in the Visual Analog Scale (VAS) score. Findings indicated that the change in VAS score was statistically different between the active and placebo groups, though the degree of change observed requires further analysis.
  • Dosing and Duration: Studies explored whether a lower dose measured the duration of any perceived change in patient-reported pain scores compared to the standard dose.

Safety and Tolerability Profiles

Initial Phase I trials primarily focused on characterizing the adverse events observed with this combination. Research has explored whether the compound was associated with changes in the metabolism of commonly prescribed anticoagulants. Studies are ongoing to determine if these changes have a clinical impact.

Key Studies & References Phase I Clinical Study on the Tolerability and Safety Profile of a Novel Indom Formulation

Frequently Asked Questions (FAQ)

Common questions about Indom (FAQ)


Q: Is Indom the same type of medicine as ibuprofen or naproxen?

Indom (Indomethacin) is officially classified as a Nonsteroidal Anti-Inflammatory Drug (NSAID). This classification describes medicines that work to reduce inflammation, pain, and fever. According to regulatory labeling, common pain relievers like ibuprofen and naproxen are also categorized within the NSAID drug class.


Q: How quickly does Indom usually start to work?

Official documentation reports on the expected timeline for symptom relief. Definite pain relief has been observed in studies within 2 to 4 hours following an initial dose for certain acute inflammatory conditions. The time taken to observe effects may be influenced by the specific condition being addressed and the medicine's formulation.


Q: How long does the effect of Indom last?

The duration of the effect is related to the specific form of the medicine. For example, the extended-release capsule is designated in regulatory documents for once daily use, suggesting it is formulated for a sustained release profile. This approach aims to maintain concentrations in the body over time.


Q: Can Indom be taken for a long time?

Regulatory documents address the use of this medicine over time. Official labeling notes that the risk of serious adverse events, particularly those affecting the heart and digestive system, may increase with the duration of use. Therefore, this medicine is generally used at the lowest effective amount for the shortest duration consistent with treatment goals.


Q: Does Indom affect alcohol consumption?

Official documentation indicates a documented risk of serious gastrointestinal adverse events when co-administered with alcohol. The official label advises caution regarding the use of this medicine when consuming alcohol.


Q: Does Indom help with all kinds of pain?

Official information indicates the medicine is authorized for the management of pain associated with specific inflammatory conditions. These include painful states like rheumatoid arthritis, osteoarthritis, bursitis, and acute gouty arthritis. It is generally not indicated for the management of all types of pain.


Q: Is feeling dizzy a typical side effect of Indom?

Yes, regulatory documents list dizziness as one of the adverse reactions that is common when taking this medicine. This effect falls under the nervous system classification of reported side effects.


Q: Can Indom affect my ability to drive?

Official patient information describes that activities like driving or operating machinery should be avoided until an individual understands how the medicine affects them. This caution is noted because adverse reactions like dizziness or impaired judgment could occur.


Q: Does Indom interact with common over-the-counter pain relievers?

Regulatory documents advise caution when using Indom with other pain relievers. This is because many common over-the-counter medicines contain ingredients similar to Indom, such as aspirin or other NSAIDs. The concurrent use of these substances is described as potentially increasing the risk of adverse events, particularly serious gastrointestinal issues.


Q: What foods or supplements interact with Indom?

Administration guidelines suggest that oral forms of the medicine are generally taken with food. While specific supplements are not universally listed, the official label notes that interactions related to food and alcohol intake have been identified.


Q: Can Indom cause weight gain?

Regulatory documentation notes that fluid retention and edema (swelling due to fluid buildup) have been observed in some patients. Official documentation suggests that patients report signs of unexplained weight gain or edema to their prescriber.


Q: Can children or teenagers use Indom?

Official pediatric use information states that the safety and efficacy of the oral capsules have not been established for children under 14 or 15 years of age for most forms. The medicine is typically reserved for adult use for most of its authorized conditions.


Q: Are there different strengths or types of Indom available?

Yes, official dosage form documentation confirms that the medicine is available in several systemic forms. These include oral capsules in various strengths, suppositories for rectal use, and an oral suspension (liquid form).


Q: Is Indom addictive or habit-forming?

Indom is classified as a non-controlled substance by regulatory authorities. This means that, unlike certain pain medications, official schedules indicate it has no potential for dependency or habit-forming behaviors.


Q: What happens if someone takes too much Indom?

Official public health guidance emphasizes that taking more than the prescribed amount of this medicine can be harmful. In such an event, professional medical assistance or a poison control center should be contacted immediately.


Q: Does Indom treat the cause of the condition or just the symptoms?

According to the official clinical pharmacology information, the medicine is described as providing relief of symptoms, such as pain, swelling, and fever. It is noted that the medicine does not alter the progressive course of the underlying disease.


Q: Is there a generic version of Indom available?

Yes, regulatory records confirm that generic versions of the active ingredient are available. This is indicated by the medicine's market status, which includes the approval of Abbreviated New Drug Applications (ANDA).


Q: Do studies show Indom is better than placebo?

Clinical studies referenced in the official labeling have found the medicine to be effective in the active stages of certain inflammatory conditions. This finding indicates that Indom provided a clinical benefit compared to a non-active agent (placebo) in those studies.


Q: Can Indom cause trouble sleeping?

Adverse reactions related to sleep have been reported in the nervous system classification. These reactions include both insomnia (difficulty sleeping) and somnolence (drowsiness).


Q: Is it normal to feel tired when starting Indom?

Regulatory documents note that fatigue and general tiredness are adverse reactions that have been associated with the use of the medicine, as reported in clinical trial data.


Q: What should I tell my doctor before starting Indom?

Official patient information stresses the importance of sharing a complete health history. Patients should ensure their prescriber is aware of all existing medical conditions, especially pre-existing issues involving the kidneys, liver, heart, or a history of ulcers or digestive bleeding.


Q: Are there any lab tests needed while taking Indom?

Regulatory documents note that periodic monitoring of certain bodily functions may be necessary during use. This may include checks on blood pressure, renal function (kidney health), and hemoglobin/hematocrit levels, particularly for individuals on long-term treatment.


Q: Can Indom cause skin rashes or allergic reactions?

Official documents list skin rash as an adverse reaction. They also list rare but severe events, such as widespread inflammation of the skin (exfoliative dermatitis) and severe whole-body allergic responses (anaphylactic reactions).


Q: Can Indom be crushed or split?

The official administration instructions specifically state that the extended-release capsules must not be crushed, broken, or chewed. This restriction is noted in regulatory documents to preserve the medication's intended release characteristics.


Q: Is there a liquid form of Indom?

Yes, an oral suspension (liquid form) is officially available as one of the systemic dosage forms. The specific availability and suitability of this form depend on the treatment needs.


Q: Does Indom lose its effectiveness over time?

For chronic conditions, the official dosing guidelines often recommend repeated attempts to reduce the dose to the smallest effective amount. This guidance suggests that ongoing assessment of the medicine's effectiveness is needed to ensure appropriate dosing.

How should Indom be stored and disposed of?

Official Storage and Disposal Requirements

Storage and disposal instructions for Indomethacin (Indom) are specific to the drug's formulation, as established by regulatory health authorities.

Formulation Required Storage Condition Handling/Protection Rule
Oral Capsules / Injection Powder Controlled Room Temperature (20°C to 25°C) Protect from light; capsules also away from moisture.
Rectal Suppositories Refrigerated (2°C to 8°C) OR below 25°C Keep in a secure location.
Oral Liquid Below 30°C Do not freeze.

All forms must be kept strictly out of the reach of children. The Indomethacin injection solution must be prepared freshly just before use; any unused portion must be immediately discarded as the solution lacks preservatives. Do not use, store, or dispose of the medicine outside of the conditions specified on the official product labeling.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Indom found in:

A-Z Index: